InvestWiser

Hansa Biopharma AB

HNSANasdaq StockholmHealthcareMarket value 4.7 bn SEK
47.32SEK −1.2%
last day · Price as of 19 November 2026

The answer first

Does Hansa Biopharma beat the market?

Yes, Hansa Biopharma has beaten the market over the last year.

Hansa Biopharma+74.2%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 23% of Nordic stocks

    • Quality15
    • Value2
    • Trend95

    No. 122 of 195 in healthcare

  • Expectations in the price

    Low expectations

    For the share to return about 9% a year from today's price, it is enough that the cash Hansa Biopharma keeps shrinks about 4% a year for 10 years.

Max for seven days

Follow Hansa Biopharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Hansa Biopharma

From today, at a price of 47.32 SEK. Write why you follow Hansa Biopharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Hansa Biopharma

Your first answer is free, no account needed.

Do you own Hansa Biopharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Hansa Biopharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Hansa Biopharma+74.2%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Hansa Biopharma has risen 74.2% over the past year, including dividends.
  • Overall, Hansa Biopharma ranks better than 23% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 90.6%. The price is 86.4% below its peak now.

What do analysts think of Hansa Biopharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

23

Quality, value and trend together. Better than 23% of Nordic stocks.

No. 122 of 195 in healthcare

Quality15
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 179 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity−1.45
  • Asset turnoverSales divided by everything the company owns0.16
  • Return on equityProfit divided by equity−116.8%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 185 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equitynegative earnings
  • P/SPrice divided by sales15.4
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flow8.8

The ranking is built on P/E, P/B and P/S.

Trend95
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 13 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+13.1%
  • 6 months+40.8%
  • 9 months+46.9%
  • 12 months+74.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+25.9%
3 years, per year
+24.7%
5 years, per year
−14.6%
10 years, per year
−8.7%
Largest fall, 3 years
−90.6%
From a peak to the bottom
From the peak now
−86.4%
How far the price is from the peak
Volatility, 1 year
66.9%
How much the price swings over a year
Beta, 1 year
1.10
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Hansa Biopharma

12 funds we follow own Hansa Biopharma. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden11

From the funds' latest known holdings.

About Hansa Biopharma

Hansa Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 120 employees.

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.

See the full analysis of Hansa Biopharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market